Treatment with small molecules. Principles and problems involved in their use for solid tumors;Therapie mit "small molecules". Grundlagen und klinische problematik in der anwendung bei soliden tumoren

Onkologe

Volumn 10, Issue 1, 2004, Pages 38-45

  Hohenberger, P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

EGF receptor; GI stromal tumor; Receptor targeting; Small molecules; Tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN;

ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DNA MICROARRAY; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK TUMOR; HUMAN; LUNG NON SMALL CELL CANCER; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; PROTO ONCOGENE; SOLID TUMOR;

EID: 1142311064     PISSN: 09478965     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00761-003-0637-4     Document Type: Article

References (34)

1. Allander SV et al. (2002) Expression profiling of synovial sarcoma by cDNA microarrays: association of ERB-B2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 16:1587-1595
2. Baselga J (2001) The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 37:S16-S22
3. Bossemeyer D (1995) Protein kinases-structure and function. FEBS Lett 369:57-61
4. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Regenass U, Lydon NB (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine calss. Proc Natl Acad Sci USA 92:2558-2562
5. Cohen S, Carpenter G, King L Jr (1980) Epidermal Growth Factor Receptor-Kinase Interactions: Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255:4834-4842
6. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003) FDA approval summary: gefitinib (ZD1839) tablets. Oncologist 8:303-306
7. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480
8. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD (1984) Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521-527
9. Druker BJ (2003) Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 40:50-58
10. Fischer T (2002) Signalübertragungshemmer-Wirkprinzip und klinische Anwendung. Unimed, Bremen
11. Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, Fletcher J, van Mehren M, Eisenberg B, Godwin AK (2003) Response Markers and the molecular mechanism of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2:669-709
12. Goldman JM (2000)Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia. Lancet 355:1031-1032
13. a. Heinrich MC et al. (2003) Kinase Mutations and Imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349
14. Hirota S, Isozaki K, Moriyama Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580
15. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nishikawa K, Ohashi A, Takabayashi A, Obayashi T, Okuno T, Kinoshita K, Chen H, Shinomura Y, Kitamura Y (2002) Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 122:1493-1499
16. Hohenberger C, Reichardt P, Stroszczynski C, Schneider U, Hossfeld DK (2003) Gastrointestinale Stromatumoten (GIST)-Tumorentität und Therapie mit Imatinib mesylat. Dtsch Ärztebl 100:A 1612-1618
17. Joensuu H, Roberts PJ, Sarloma-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056
18. Jost D, Stroszczynski C, Chmelik P, Gaffke G, Schlecht I, Pink D, Reichardt P, Schneider U, Hohenberger P, Felix R (2003) Morphologie gastrointestinaler Stromatumoren im fortgeschrittenen Stadium der Erkrankung. Röfo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 175:791-798
19. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ (2003) Blockade of Epidermal Growth Factor Receptor Signaling in Tumor Cells and Tumor-associated Endothelial Cells for Therapy of Androgen-independent Human Prostate Cancer Growing in the Bone of Nude Mice. Clin Cancer Res 9:1200-1210
20. Lux ML, Rubin BP, Biase TL, Chen C-J, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CDM, Fletcher JA (2000) KIT extracellular and kinase dmain mutations in gastrointestinal stromal tumors. Am J Pathol 156:791-795
21. Mendelsohn J (2002) Targeting the Epidermal Growth Factor Receptor for Cancer Therapy. J Clin Oncol 20:S14-S22
22. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D, van de Rijn M (2002) Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359:1301-1307
23. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy Cancer Res 62:5476-5484
24. Pietras RJ (2003) Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 9:361-373
25. Reichardt P, Schneider U, Stroszczynski C, Pink D, Hohenberger P (2003) Histological response of gastrointestinal stromal tumor to treatment with tyrosine kinase inhibitor imatinib mesylate. J Clin Pathol 56 (im Druck)
26. Reuter CW, Morgan MA, Bergmann L (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96:1655-1669
27. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD (2002) Molecular targeting of Platelet-Derived Growth Factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586-3591
28. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942
29. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CDM (2002) Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors. J Clin Oncol 20:3898-3905
30. Topaly J, Zeller WJ, Fruehauf S (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL positive chronic myelogenous leukaemia cells. Leukemia 15:342-347
31. Torrance CJ, Jackson PE, Montgomery E (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024-1028
32. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ (2003) Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95:458-470
33. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:148-425
34. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. The Lancet 358:1421-1423